代理软件fg下载

Cervical cancer is the second most common cancer among women aged 15 to 44, affecting more than 500,000 women a year.1 Fortunately, it is almost 100% preventable through advanced screening and early detection of precancer before the disease becomes a danger to a patient’s life or reproductive health.

QIAsure, the new Women’s Health solution from QIAGEN, is a cervical cancer screening test that lets clinicians see what’s happening at a molecular level to determine whether cervical cells are actively transforming into cancer. This innovative test objectively detects the presence of biomarkers associated with cervical precancer and cancer in the PCR lab, using the same sample from an HPV or liquid-based cytology test. Whether the result is positive or negative, QIAsure can provide peace of mind for patients so they can live their lives safe, confident, and sure of their reproductive health.

landeng破解版安卓版

代理软件fg下载

Download a brochure for more information

代理软件fg下载

Today, women have an 80% chance in their lifetimes of contracting high-risk HPV, the causal agent of cervical cancer. However, only 1 in 10 women with high-risk HPV will develop long-lasting infections that put them at risk for development of cervical cancer.2 There is growing need for an accurate molecular test to see beyond HPV and determine whether a patient has a high short-term risk of cervical cancer.

QIAsure delivers objective assurance that women are safe from cervical cancer following a positive high-risk HPV result or an abnormal cytology result.

QIAsure could:

  • Separate out patients with high-risk HPV infections that are transforming into cervical cancer from patients who have low short-term risk of developing cancer
  • Guide surveillance and treatment decisions
  • Prevent women with non-transforming infections from receiving unnecessary treatments

代理软件fg下载

QIAsure has been developed for ease of use in primary screening scenarios, following a positive high-risk HPV result or an abnormal cytology result. QIAsure can be performed on the same sample used for primary screening (HPV and/or liquid-based cytology), as well as vaginal self-samples collected by patients.

betternet中文版下载

QIAsure is a quantitative methylation specific (qMSP) test that looks for specific molecular biomarkers in cervical specimens to objectively detect the presence of biomarkers associated with cervical carcinoma and advanced transforming cervical intraepithelial neoplasia (CIN). The presence of these biomarkers (specifically hypermethylation of host cell genes FAM19A4 and miR124-2) indicates a carcinogenic cell transformation and a high short-term risk of developing cervical cancer.3–8 Absence of these biomarkers indicates a low short-term risk of developing cervical cancer. This test can be performed in the PCR lab through industry-standard methods of sample prep/extraction and automation platforms for analysis (clinically validated for Rotor-Gene® Q MDx instrument).

QIAsure has been shown to detect the transformation of cervical cells and advanced transforming CIN 2/3 lesions, even in patients with normal cytology.

代理软件fg下载

QIAsure is a quantitative methylation specific PCR test with high sensitivity and 100% accuracy in detecting biomarkers associated with cervical carcinoma in patients.

betternet破解版android

QIAsure provides objective results on whether a patient has a hrHPV infection that’s actively transforming cervical cells into cancer.

Android使用GoogleMap v2(一)_移动开发_weixin_30551963 ...:2021-2-22 · 说明由于国内使用v2最新的谷歌地图有很多限制,所有如果要在真机上测试运行要做一些准备 准备1: vpn必不可少啦 推荐cloud vpn或者betternet都是不错的免费vpn 准备2: ... 博文 来自： abfdada的博客

QIAsure can help reduce unnecessary colposcopies and cervical treatments.

QIAsure can be performed on self-samples collected by the patient without a speculum exam, making it easy and convenient to be tested early and often.

Betternet安卓版下载

翻牆 VPN 推薦哪一家？Betternet 免費翻牆 10 個國家 | 綠 …:Betternet 免費 VPN 一鍵翻牆支援 10 個國家，免費VPN,免費VPN翻牆,免費VPN工具下載,免費手機VPN,Betternet VPNVPN 可以跨國買貼圖、下載遊戲等，繼之前分享的 VPN Gate 免費穩定 VPN 中繼伺服器之後，今天又要來跟大家分享一款全平台都能使用的免費 ...

Veronica has a high-risk HPV infection and returns for her six-month follow-up appointment. A pap smear discovers abnormal cytology and she undergoes colposcopy to look for precancerous lesions. Low-grade lesions are present, however the level of short-term risk is unclear since there are no molecular insights into whether the lesions are actively transforming into cancer or could subside on their own. QIAsure is performed for more insight into what’s happening at a molecular level before making a clinical decision for Veronica. betternet破解版android betternet破解版最新apk age 30
Sophie undergoes primary screening for HPV and discovers she is at risk for cervical cancer due to detection of high-risk HPV. QIAsure is performed on the same sample to look for the presence of precancer or cancer. QIAsure produces a negative result and the clinician schedules a six-month follow-up appointment. QIAsure separates transforming high-risk HPV infections from non-transforming infections so that Sophie can be confident she is safe from cancer. Betternet安卓 landeng破解版安卓版
Emma has high-risk HPV, but normal cytology. A QIAsure test produces a positive result, indicating the presence of transforming precancer. Emma is sent straight to colposcopy and treated for advanced transforming precancerous lesions. Without the QIAsure test, she would have had to wait 6 months before being re-tested, putting her life and reproductive health at risk. QIAsure identifies transforming high-risk HPV infections that can be missed by cytology and genotyping so that Emma is safe from dangerous precancer that could have rapidly progressed to cancer. Emma age 34